In a recent development, Palantir's UK operations have come under scrutiny as government ministers consider terminating their £330m contract with the NHS. This move has sparked a debate about the role of ideologically driven entities in public sector contracts, with Palantir's UK boss, Louis Mosley, urging the government to resist pressure from campaigners. Mosley argues that the company's software has proven beneficial, citing a projected £150m in benefits by the end of the decade.
The Federated Data Platform (FDP), an AI-enabled data system designed by Palantir, aims to connect various health information across the NHS. However, concerns have been raised about the company's presence in the public sector, with ministers seeking advice on invoking a break clause in the contract.
Palantir, named after the all-seeing orbs in Tolkien's Lord of the Rings, has a diverse client base, including the Israeli and US militaries and Donald Trump's ICE operation. The British Medical Association (BMA) has long opposed Palantir's involvement in the NHS, citing ethical concerns.
Health officials worry that Palantir's reputation could hinder the delivery of the FDP contract. Sources close to the health secretary, Wes Streeting, highlight his recognition of public worries about the deal, especially given Palantir's founder, Peter Thiel's, right-wing political views.
Despite these concerns, Streeting emphasizes that Palantir does not have access to patient data. The number of NHS organizations using Palantir technology has grown, but it still falls short of the target.
One Labour MP, Clive Lewis, notes that Palantir is becoming a topic of concern among voters, reflecting broader anxieties about AI and technological change. He suggests that Whitehall may be reevaluating the wisdom of embedding companies like Palantir in critical infrastructure, especially given Britain's unique vulnerabilities.
This debate raises important questions about the balance between technological advancement and ideological considerations in public sector contracts. As the government navigates this complex issue, the future of Palantir's involvement in the NHS remains uncertain.
